Structure and regulation of Kit protein-tyrosine kinase - The stem cell factor receptor

Biochemical and Biophysical Research Communications

Volumn 338, Issue 3, 2005, Pages 1307-1315

  Roskoski Jr , Robert ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abl; Activation loop; Acute myelogenous leukemia; Bcr Abl; Cell signaling; Chronic myelogenous leukemia; Dysgerminoma; Flt3; Germ cells; Gleevec; Mast cells; Nasal T cell lymphoma; Oncogene; Proto oncogene; Seminoma; STI 571; Targeted cancer therapy

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; IMATINIB; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR;

AMINO ACID SUBSTITUTION; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; ENZYME REGULATION; HUMAN; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW;

EID: 27744551009     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2005.09.150     Document Type: Short Survey

References (43)

1. P. Cohen The origins of protein phosphorylation Nat. Cell Biol. 4 2002 E127 E130
2. P. Cohen Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1 2002 309 315
3. G. Manning G, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
4. R. Roskoski Jr. Src protein-tyrosine kinase structure and regulation Biochem. Biophys. Res. Commun. 324 2004 1155 1164
5. Y. Yarden, W.J. Kuang, T. Yang-Feng, L. Coussens, S. Munemitsu, T.J. Dull, E. Chen, J. Schlessinger, U. Francke, and A. Ullrich Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand EMBO J. 6 1987 3341 3351
6. W.J. Fantl, D.E. Johnson, and L.T. Williams Signaling by receptor tyrosine kinases Annu. Rev. Biochem. 62 1993 453 481
7. Z. Zhang, R. Zhang, A. Joachimiak, J. Schlessinger, and X.P. Kong Crystal structure of human stem cell factor: implication for stem cell factor receptor dimerization and activation Proc. Natl. Acad. Sci. USA 97 2000 7732 7737
8. L. Rönnstrand Signal transduction via the stem cell factor receptor/c-Kit Cell. Mol. Life Sci. 61 2004 2535 2548
9. L. Palmqvist, C.H. Glover, L. Hsu, M. Lu, B. Bossen, J.M. Piret, R.K. Humphries, and C.D. Helgason Correlation of murine embryonic stem cell gene expression profiles with functional measures of pluripotency Stem Cells 23 2005 663 680
10. P. Blume-Jensen, L. Claesson-Welsh, A. Siegbahn, K.M. Zsebo, B. Westermark, and C.H. Heldin Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis EMBO J. 10 1991 4121 4128
11. R. Roskoski Jr. Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor Biochem. Biophys. Res. Commun. 337 2005 1 13
12. P. Blume-Jensen, R. Janknecht, and T. Hunter The kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136 Curr. Biol. 8 1998 779 782
13. Y. Kitamura, and S. Hirota Kit as a human oncogenic tyrosine kinase Cell. Mol. Life Sci. 61 2004 2924 2931
14. C.D. Mol, K.N. Lim, V. Sridhar, H. Zou, E.Y. Chien, B.C. Sang, J. Nowakowski, D.B. Kassel, C.N. Cronin, and D.E. McRee Structure of a c-kit product complex reveals the basis for kinase transactivation J. Biol. Chem. 278 2003 31461 31464
15. C.D. Mol, D.R. Dougan, T.R. Schneider, R.J. Skene, M.L. Kraus, D.N. Scheibe, G.P. Snell, H. Zou, B.C. Sang, and W.P. Wilson Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase J. Biol. Chem. 279 2004 31655 31663
16. M. Huse, and J. Kuriyan The conformational plasticity of protein kinases Cell 109 2002 275 282
17. B. Nolen, S. Taylor, and G. Ghosh Regulation of protein kinases; controlling activity through activation segment conformation Mol. Cell 15 2004 661 675
18. S.K. Hanks, A.M. Quinn, and T. Hunter The protein kinase family: conserved features and deduced phylogeny of the catalytic domains Science 241 1988 42 52
19. S.S. Taylor, E. Radzio-Andzelm, and T. Hunter How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase FASEB J. 9 1995 1255 1266
20. S.R. Hubbard Juxtamembrane autoinhibition in receptor tyrosine kinases Nat. Rev. Mol. Cell Biol. 5 2004 464 471
21. S.R. Hubbard, and J.H. Till Protein tyrosine kinase structure and function Annu. Rev. Biochem. 69 2000 373 398
22. C.D. Mol, D. Fabbro, and D.J. Hosfield Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors Curr. Opin. Drug Discov. Dev. 7 2004 639 648
23. E. Martz Protein Explorer: easy yet powerful macromolecular visualization Trends Biochem. Sci. 27 2002 107 109
24. J. Griffith, J. Black, C. Faerman, L. Swenson, M. Wynn, F. Lu, J. Lippke, and K. Saxena The structural basis for autoinhibition of FLT3 by the juxtamembrane domain Mol. Cell 13 2004 169 178
25. M. Heinrich, C.D. Blanke, B.J. Druker, and C.L. Corless Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies J. Clin. Oncol. 20 2002 1692 1703
26. G.W. Krystal, S.J. Hines, and C.P. Organ Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor Cancer Res. 56 1996 370 376
27. K. Kemmer, C.L. Corless, J.A. Fletcher, L. McGreevey, A. Haley, D. Griffith, O.W. Cummings, C. Wait, A. Town, and M.C. Heinrich KIT mutations are common in testicular seminomas Am. J. Pathol. 64 2004 305 313
28. C. Akin, and D.D. Metcalfe Systemic mastocytosis Annu. Rev. Med. 55 2004 419 432
29. R.T. Oliver, M.D. Mason, G.M. Mead, H. Von der Maase, G.F. Rustin, J.K. Joffe, R. De Wit, N. Aass, J.D. Graham, R. Coleman, S.J. Kirk, and S.P. Stenning Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial Lancet 366 2005 293 300
30. K.H. Lu, and D.M. Gershenson Update on the management of ovarian germ cell tumors J. Reprod. Med. 50 2005 417 425
31. T. Sanda, S. Lida, M. Ito, K. Tsuboi, K. Miura, S. Harada, H. Komatsu, A. Wakita, H. Inagaki, and R. Ueda Successful treatment of nasal T-cell lymphoma with a combination of local irradiation and high-dose chemotherapy Int. J. Hematol. 75 2002 95 200
32. C.L. Corless, J.A. Fletcher, and M.C. Heinrich Biology of gastrointestinal stromal tumors J. Clin. Oncol. 22 2004 3813 3825
33. S. Hirota, K. Isozaki, Y. Moriyama, K. Hashimoto, T. Nishida, S. Ishiguro, K. Kawano, M. Hanada, A. Kurata, M. Takeda, G. Tunio, Y. Matsuzawa, Y. Kanakura, Y. Shinomura, and Y. Kitamura Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 1998 577 580
34. M.D. Heinrich, C.L. Corless, G.D. Demetri, C.D. Blanke, M. von Mehren, H. Joensuu, L.S. McGreevey, C.J. Chen, A.D. Van den Abbeele, B.J. Druker, B. Kiese, B. Eisenberg, P.J. Roberts, S. Singer, C.D. Fletcher, S. Silberman, S. Dimitrijevic, and J.A. Fletcher Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J. Clin. Oncol. 21 2003 4342 4349
35. T. Hongyo, T. Li, M. Syaifudin, R. Baskar, H. Ikeda, Y. Kanakura, K. Aozasa, and T. Nomura Specific c-kit mutations in sinonasal natural killer/T-cell lymphoma in China and Japan Cancer Res. 60 2000 2345 2347
36. H. Kitayama, Y. Kanakura, T. Furitsu, T. Tsujimura, K. Oritani, H. Ikeda, H. Sugahara, H. Mitsui, Y. Kanayama, Y. Kitamura, and Y. Matsuzawa Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines Blood 85 1995 790 798
37. R. Roskoski Jr. STI-571: an anticancer protein-tyrosine kinase inhibitor Biochem. Biophys. Res. Commun. 309 2003 709 717
38. B. Nagar, W.G. Bornmann, P. Pellicena, T. Schindler, D.R. Veach, W.T. Miller, B. Clarkson, and J. Kuriyan Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res. 62 2002 4236 4243
39. L.L. Chen, M. Sabripour, R.H. Andtbacka, S.R. Patel, B.W. Feig, H.A. Macapinlac, H. Choi, E.F. Wu, M.W. Frazier, and R.S. Benjamin Imatinib resistance in gastrointestinal stromal tumors Curr. Oncol. Rep. 7 2005 293 299
40. M.S. Cohen, C. Zhang, K.M. Shokat, and J. Taunton Structural bioinformatics-based design of selective, irreversible kinase inhibitors Science 308 2005 1318 1321
41. R. Roskoski Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer Biochem. Biophys. Res. Commun. 319 2004 1 11
42. Y. Kimura, N. Jones, M. Kluppel, M. Hirashima, K. Tachibana, J.B. Cohn, J.L. Wrana, T. Pawson, and A. Bernstein Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages Proc. Natl. Acad. Sci. USA 101 2004 6015 6020
43. A.S. Corbin, S. Demehri, I.J. Griswold, Y. Wang, C.A. Metcalf 3rd, R. Sundaramoorthi, W.C. Shakespeare, J. Snodgrass, S. Wardwell, D. Dalgarno, J. Iuliucci, T.K. Sawyer, M.D. Heinrich, B.J. Druker, and M.W. Deininger In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit Blood 106 2005 227 234